Oblenio Bio

Oakland, United States

Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment.

$62.0M raised

Jun 2026

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Oblenio Bio raised?

Oblenio Bio has raised $62.0M in total funding. The most recent round was Series B. The last funding was announced in June 2026.

Who are Oblenio Bio's investors?

Oblenio Bio's investors include Pfizer Venture Investments, Deep Track Capital, Aditum Bio, GV.

Where is Oblenio Bio headquartered?

Oblenio Bio is headquartered in Oakland, United States.

What does Oblenio Bio do?

Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment.

What stage is Oblenio Bio at?

Oblenio Bio is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 25, 2026.

MLA

"Oblenio Bio — Funding & Investors." VCBacked, June 25, 2026, https://www.vcbacked.co/company/oblenio-bio. Accessed July 2, 2026.

APA

VCBacked. (2026). Oblenio Bio — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/oblenio-bio

Wikipedia (cite web)

{{cite web |title=Oblenio Bio — Funding & Investors |url=https://www.vcbacked.co/company/oblenio-bio |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 25, 2026.